Shares of AC Immune SA (NASDAQ:ACIU) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $23.00 for the company and are forecasting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned AC Immune an industry rank of 98 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a report on Thursday, November 16th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Belpointe Asset Management LLC bought a new position in shares of AC Immune during the 3rd quarter valued at about $571,000. Janney Montgomery Scott LLC bought a new position in shares of AC Immune during the 3rd quarter valued at about $134,000. Wells Fargo & Company MN bought a new position in shares of AC Immune during the 3rd quarter valued at about $111,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of AC Immune during the 2nd quarter valued at about $127,000. 17.12% of the stock is owned by institutional investors and hedge funds.

AC Immune (NASDAQ ACIU) opened at $11.85 on Friday. AC Immune has a 1-year low of $6.03 and a 1-year high of $15.00.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/03/zacks-ac-immune-sa-aciu-given-consensus-rating-of-strong-buy-by-analysts.html.

AC Immune Company Profile

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.